8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
Moderna reports $145 million Q2 revenue and narrows 2026 expense outlook
Filed with the SEC on · Summarized by InvestorsBot
Moderna reported second-quarter 2026 revenue of $145 million for the period ended June 30, up from $142 million a year earlier, while its GAAP net loss improved to $782 million, or $1.97 per share, from $825 million, or $2.13 per share. The company reiterated its plan for up to 10% revenue growth in 2026, lowered its operating expense outlook by about $200 million, and raised projected year-end cash and investments to $4.7 billion-$5.2 billion; it also said its norovirus vaccine failed to meet early-success criteria in a Phase 3 interim analysis and is preparing to enroll another cohort, while mFLUSIVA faces a potential U.S. approval decision on August 5, 2026.